Kardatuxan

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for prevention of stroke and systemic embolism in non‑valvular atrial fibrillation and for treatment and secondary prevention of deep‑vein thrombosis and pulmonary embolism, including postoperative thromboprophylaxis after hip or knee replacement. GNH USA supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kardatuxan, a direct factor Xa inhibitor, is employed in several thrombo‑embolic conditions. - Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis and pulmonary embolism: treats acute events and prevents recurrence. - Post‑operative thromboprophylaxis: lowers incidence of clot formation after hip or knee replacement surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bleeding (including gastrointestinal and mucosal). - Bruising or hematoma formation. - Nausea or dyspepsia. - Diarrhea. - Headache. - Dizziness.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions (anaphylaxis, angioedema). - Elevated liver enzymes or hepatic injury. - Myocardial infarction or acute coronary syndrome.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately. - Renal impairment: adjust use based on creatinine clearance. - Hepatic disease: avoid in patients with significant liver dysfunction. - Concomitant antiplatelet or NSAID therapy: increase bleeding risk. - Upcoming surgery or invasive procedures: discontinue according to clinical guidelines. - Pregnancy and breastfeeding: generally contraindicated due to limited safety data. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Rivaroxaban may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, heparin). - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine). - Potent P‑glycoprotein inhibitors (e.g., verapamil). - Antiplatelet agents (e.g., clopidogrel, aspirin).

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin). - Moderate P‑glycoprotein inhibitors (e.g., amiodarone). - Selective serotonin reuptake inhibitors (SSRIs). - Diuretics that may affect renal function. - Herbal products such as St. John’s wort.